view counter

Category: VascularSyndicate content

Vascular

UPDATE: Atrium fires back at Bard over patent infringement suit

August 18, 2010 by MassDevice staff

Atrium Medical Corp. fires back at C.R. Bard Inc. over a lawsuit accusing Atrium and Endologix Inc. of infringing a Bard patent for prosthetic vascular grafts made from expanded polytetrafluoroethylene.

BCR, Atrium, ELGX logos

C.R. Bard Inc.'s (NYSE:BCR) peripheral vascular unit sued a pair of competitors over a patent covering its prosthetic vascular grafts made from expanded polytetrafluoroethylene.

The lawsuit, filed in the U.S. District Court for Arizona, accuses Endologix Inc. (NSDQ:ELGX) and Atrium Medical Corp. of infringing Bard's patent for "Prosthetic Vascular Graft." Bard alleges that Atrium's Advanta line of grafts and stents, its iVena vascular patch and Flixene graft violate the patent and that Endologix runs afoul with its Powerlink stent grafts.

Strong Q2 Prompts LeMaitre Vascular to Boost 2010 Guidance

July 29, 2010 by MassDevice staff

LeMaitre Vascular turns in $1.5 million, second-quarter profit as sales climb 12% from year-ago levels; Firm says 2010 revenues should hit $55.8 million, up nearly $5 million from 2009

After easily beating Wall Street estimates for the second quarter, LeMaitre Vascular Inc. (Nasdaq:LMAT) is boosting guidance for the rest of 2010.

The Burlington, Mass.-based maker of stents, grafts, carotid shunts, catheters and vascular surgical tools said that sales during the three months ended June 30 reached $14.2 million, a 12 percent bump over the same span in 2009 and topping consensus analyst opinion for the quarter by roughly $500,000. Net income was $1.5 million, a 63 percent increase from the $925,000 profit LeMaitre reported in the June 2009 quarter.

UPDATE: Covidien closes ev3 buyout

July 12, 2010 by MassDevice staff

Hours after announcing the close of its $22.50-per-share tender offer for ev3 Inc., Covidien plc announces the consummation of the $2.6 billion buyout of the Minnesota vascular device maker.

COV, EVVV logos

Covidien plc (NYSE:COV) consummated a $2.6 billion deal to acquire ev3 Inc. (NSDQ:EVVV), hours after closing its tender offer for shares in the Minnesota vascular device maker.

Mansfield, Mass.-based Covidien shelled out $22.50 per share for about 100.8 million ev3 shares. That $2.27 billion gave it roughly 87.7 percent of ev3's outstanding shares and cleared the way for a Covidien holding company to complete the merger without any further input from ev3 stockholders.

Ev3 to settle shareholder lawsuits over Covidien buyout

July 8, 2010 by MassDevice staff

Ev3 Inc. agrees to settle lawsuits filed by shareholders seeking to block its $2.6 billion buyiout by Covidien plc.

COV, EVVV logos

ev3 Inc. (NSDQ:EVVV) agreed to settle a group of lawsuits filed by shareholders looking to block its $2.6 billion buyout by Covidien plc (NYSE:COV).

The lawsuits, filed in the Hennepin County District Court for Minnesota and Delaware's Court of Chancery, accused the Plymouth, Minn.-based company's board of breaching its fiduciary duties in giving a green light to the merger and of failing to disclose how it evaluated the offer from Covidien, according to regulatory filings.

Covidien inks $2.6 billion buyout of ev3

June 1, 2010 by MassDevice staff

Covidien plc expands its peripheral vascular footprint with a $2.6 billion acquisition of ev3 Inc.

COV, EVVV logos

Covidien plc (NYSE:COV) agreed to acquire ev3 Inc. (NSDQ:EVVV) for about $2.6 billion in cash in a move that substantially expands its footprint in the peripheral vascular market.

Connecticut device makers tout approvals for surgical implements

May 21, 2010 by MassDevice staff

SurgiQuest Inc. and Vascular Insights LLP may commence sale of two new surgical devices.

SurgiQuest, Vascular Insights logos

A pair of Connecticut medical device firms won regulatory nods in the U.S. and Europe.

SurgiQuest Inc. won 510(k) clearance from the Food & Drug Administration for its new line of 5mm AnchorPort laparoscopy trocars and Vascular Insights LLP landed CE Mark approval in Europe for its ClariVein Occlusion Catheter.

SurgiQuest touts its device's ability to adjust for differences in each patient, calling it "the world's first elastomeric single incision laparoscopy kit."

Covidien inks provider deal for 122-clinic network

May 12, 2010 by MassDevice staff

Covidien plc enters a sole-source agreement for anti-deep vein thrombosis products with the Upper Midwest Consolidated Service Center and Mayo Clinic.

COV logo

Mansfield, Mass.-based medical products conglomerate Covidien plc inked a sole-source agreement with the Upper Midwest Consolidated Service Center and Mayo Clinic for its anti-deep vein thrombosis products.

Covidien's Kendall SCD Sequential Compression System and A-V Impulse System Foot Pump will be distributed in 122 hospitals across 10 states.

Support the news, become a MassDevice.com insider
view counter
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp